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Abstract
Background: Hepatitis C is a major health problem causes liver cirrhosis, hepatocellular carcinoma and death. The
current treatment of standard interferon in combination with ribavirin, has limited benefits due to emergence of
resistant mutations during long-term treatment, adverse side effects and high cost. Hence, there is a need for the
development of more effective, less toxic antiviral agents.
Results: The present study was designed to search anti-HCV plants from different areas of Pakistan. Ten medicinal
plants were collected and tested for anti-HCV activity by infecting the liver cells with HCV 3a innoculum. Methanol
and chloroform extracts of Solanum nigrum (SN) seeds exhibited 37% and more than 50% inhibition of HCV
respectively at non toxic concentration. Moreover, antiviral effect of SN seeds extract was also analyzed against
HCV NS3 protease by transfecting HCV NS3 protease plasmid into liver cells. The results demonstrated that
chloroform extract of SN decreased the expression or function of HCV NS3 protease in a dose- dependent manner
and GAPDH remained constant.
Conclusion: These results suggest that SN extract contains potential antiviral agents against HCV and combination
of SN extract with interferon will be better option to treat chronic HCV.
Introduction
An estimated 3% of the world’s population (270 million
people) is chronically infected by HCV which is the
main cause of liver fibrosis and cirrhosis that leads to
hepatocellular carcinoma (HCC) in a significant number
of patients [1,2]. Almost 10 million people in Pakistan
are living with HCV [3] and the most prevalent HCV
genotype is 3a followed by 3b and 1a [4]. HCV is envel-
oped, positive strand RNA genome comprising 9.6 kb of
uncapped RNA [5,6]. The internal ribosomal entry site
(IRES) is located within the 5’UTR of the HCV genome
that initiates translation of a large precursor polyprotein,
which is processed by cellular and viral proteinases to
form 10 viral proteins, specifically Core, E1, E2, p7
(structural proteins), NS2, NS3, NS4a, NS4b, NS5a and
NS5b (nonstructural proteins) [6-8]. The nonstructural
proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B)
provide enzymes essential for protein processing and
RNA replication; their functions include protease, RNA
helicase, and RNA polymerase activity [9].
However, there is no vaccine available for HCV and
40-50% of patients fail to respond to current therapies
of PEG-INF/Ribavirin [10]. Neither interferon (INF)
monotherapy, nor a combination of IFN or ribavirin,
have been able to eradicate HCV replication in the
majority of patients [11]. The modified forms of IFN,
such as Pegylated IFN, etc. are available and the rate of
sustained virologic response (SVR) in the patients
receiving Pegylated-interferon a was 39% [12]. The SVR
rate for 1a genotype is (about 40-50%) [13] and geno-
type 2 and 3 is (about 70-80%) [14]. Furthermore, the
incidence of adverse effects (including headache, fatigue,
myalgia, depression, neutropenia, and thrombocytope-
nia) in patients receiving PEG interferon was similar to
that in patients receiving standard interferon and leads
to discontinuation of therapy.
Herbal medicines have been used for centuries against
different ailments including viral diseases and become a
focal point to identify, isolate and purify new entities to
treat diseases like Hepatitis C. According to an estimate,
25% of the commonly used medicines contain compounds
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medications is indeed plants, such as aspirin from white
Willow bark, digitalis from foxglove, warfarin (Coumadin)
from sweet clover, antimalarial drug quinine from the
bark of Cinchona officinalis, taxol isolated from the Yew
plant and digoxin from Digitalis purpurea [15]. Medicinal
compounds derived from plant extracts, are of lifelong
interest to the pharmaceutical industry. For example, taxol
is an antineoplastic drug obtained from the bark of the
Western yew tree, found to be useful in the treatment of
breast cancer [16]. Plants contain a variety of chemically
active compounds such as flavonoids, terpenoids, lignans,
sulphides, polyphenolics, coumarins, saponins, furyl
compounds, alkaloids, polyines, thiophenes, proteins and
peptides, which prone to inhibit the replication cycle of
various types of DNA or RNA viruses. A survey of pre-
sently available and those that are yet to be exploited
reveals an innumerable potentially useful phytochemicals
waiting to be evaluated and exploited for therapeutic
applications against genetically and functionally diverse
virus families such as Hepatitis C Virus [17].
The present study is an attempt to lay foundation for
screening the potential anti-HCV agents from medicinal
plants. For this reason, plant material from ten different
traditional medicinal plants were collected, soaked in
methanol, concentrated and dried. Different concentra-
tions of extracts lower than 100 μg/μl was checked for
toxicity in in-vitro culture of Huh-7 cell line. Antiviral
screening of the plant extracts was done on liver cells
and HCV RNA (viral load) is determined by Quantita-
tive Real Time RT-PCR. Thus, this information can be
useful in the theoretical design of drugs with favorable,
improved specificity and activity.
Materials and methods
Serum Sample Collection
The local HCV-3a patient’s serum samples used in this
investigation were obtained from the CAMB (Center for
Applied Molecular Biology) diagnostic laboratory,
Lahore, Pakistan. Serum samples were stored at -80°C
prior to viral inoculation experiments. Quantification
and genotype was assessed by CAMB diagnostic labora-
tory, Lahore, Pakistan. Patient’s written consent and
approval for this study was obtained from institutional
ethics committee.
Collection and Extraction of Medicinal plants
Ten different plants were selected and dried on the basis
of their medicinal characteristics. These indigenous
plants were collected from different zones of Pakistan
having different habitat. The plant species were legiti-
mated at Department of Botany, University of the Punjab,
Lahore. Plants or their parts were dried under shade at
room temperature, weighed and macerated in methanol
for overnight. Temperature would not exceed from 38°C
which is the most desirable temperature for enzymatic
activity. After 24 h solvents were filtered, residue was
soaked again in fresh solvent. Process of filtration was
repeated over 3-4 days. Methanolic extracts exhibiting
antiviral activity were further partitioned in Chloroform,
Acetone and n-Hexane. Solvents were selected on
the basis of polarity for characterization of antiviral
compounds. Extracts were weighed and their %age yield
was calculated.
Stock solution preparation
50 mg of each dried plant extract was suspended in one
ml of Dimethyl sulfoxide (DMSO) ensuring stock con-
centration of 50 μg/μl. Sieving the above solution by
using 0.22 um filter inside Laminar Flow Hood, storing
at -20°C.
Cell line
The Huh-7 cell line was compassionately offered by
Dr. Zafar Nawaz (Biochemistry and Molecular Biology
Department, University of Miami, USA). Huh-7 cells
were cultured in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum &
100 IU/ml penicillin & 100 μg/ml streptomycin, at 37°C
in an atmosphere of 5% CO2.
MTT assay for toxicity
To investigate cellular toxicity, 2 × 10
4 cells/well was pla-
ted into 96-well plates. After 24 h, different concentra-
tions of Herbal extracts were added and the plate was
sealed and kept at 37°C in an atmosphere of 5% CO
2 for
24 h. After the herbal extracts treatment was over,
removed the media and test compounds. 100 μlf r e s h
media and 20 μl of MTT solution (5 mg/ml in PBS) were
added to all wells in Columns 1-11. Wrapped the plate in
aluminium foil and incubated for 3-4 h at 37°C. Media
was carefully removed and added 100 μl of DMSO to dis-
solve the formazan crystals in Columns 1-11. MTT for-
mazan product was determined by measuring absorbance
with an enzyme-linked immunosorbent assay (ELISA)
plate reader at a test wavelength of 570 nm and a refer-
ence wavelength of 620 nm.
Cell viability was obtained using the following equation:
Percent cell viability Test 57 nm 62 nm Control 57 nm 62 n =− 00 00 –/ m m1 () *0
Anti-HCV analysis of plant extracts on Huh-7 cells
Huh-7 cell line was used to establish the in-vitro repli-
cation of HCV. A similar protocol was used for viral
inoculation as established by Zekari et al. 2009 [18] and
El-Awardy et al. 2006 [19]. High viral titer > 1 × 10
8
IU/ml from HCV-3a patient’s was used as principle
inoculum in these experiments. Huh-7 cells were
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washed twice with serum-free medium, then inoculated
with 500 μl( 5×1 0
7IU/well) and 500 μl serum free
media. Cells were maintained overnight at 37°C in 5%
CO2. Next day, adherent cells were washed three times
with 1 × PBS, complete medium was added and incuba-
tion was continued for 48 hrs. Cells were harvested and
assessed for viral RNA quantification by Real Time PCR.
To analyze the effect of Medicinal plant extracts on
HCV infection, serum infected Huh-7 cells were again
seeded after three days of infection in 24-well plates in
t h ep r e s e n c ea n da b s e n c eo fh e r b a le x t r a c t sa n dg r o w n
to 80% confluence with 2 ml medium. After 24 h, cells
and total RNA was isolated by using Gentra RNA isola-
tion kit (Gentra System Pennsylvania, USA) according
to the manufacturer’s instructions. Briefely, cells were
lysed with cell lysis solution containing 5 μl internal
control (Sacace Biotechnologies Caserta, Italy). RNA
pallet was solubilized in 1% DEPC (Diethyl pyrocarbo-
nate treated water). HCV RNA quantifications were
determined by Real Time PCR Smart Cycler II system
(Cepheid Sunnyvale, USA) using the Sacace HCV quan-
titative analysis kit (Sacace Biotechnologies Caserta,
Italy) according to the manufacturer’s instructions.
Formula for the calculation of HCV RNA concentration
Following formula was used to calculate the concentra-
tion HCV RNA of each sample.
Cy3STD Res
Fam  STD Res
coefficient IC IU HCV mL
/
./
/ ×=
IC = internal control, which is specific for each lot.
Antiviral analysis of SN extract against HCV NS3 Protease
For transfection studies, Huh-7 cells (5 × 10
4)w e r e
plated in 24-well plates for 24 h. The medium was
removed and cells were washed with 1× PBS. Cells were
transiently transfected with expression plasmids contain-
ing HCV NS3 protease in the presence and absence of
SN 100 μg extract and interferon by using Lipofecta-
mine™ 2000 (Invitrogen life technologies, Carlsbad, CA)
according to the manufacturer’sp r o t o c o l .T o t a lR N A
was extracted by using Trizol reagent (Invitrogen life
technologies, Carlsbad, CA) according to the manufac-
turer’s protocol. To analyze the effect of SN against
HCV NS3 gene, cDNA was synthesized with 1 μgo f
RNA, using Revert Aid TM First Strand cDNA Synth-
esis Kit (Fermentas, St. Leon-Rot/Germany). Gene
expression analysis was carried out via PCR (Applied
Biosystems Inc, USA) by using 2× PCR Mix (Fermen-
tas). Following primers were used for the amplification
of HCV NS3 forward primer: GGACGACGATGA-
CAAGGACT; NS3 reverse: CCTCGTGACCAGGT
AAAGGT; GAPDH Forward: ACCACAGTCCATGC
CATCAC: and GAPDH reverse; TCCACCACCCTGTT
GCTGTA PCR was performed by initial denaturation at
95°C for 5 min followed by 30 cycles, each of denatura-
tion at 92°C for 45 s, annealing at 58°C for 45 s, and
extension at 72°C for 1 min, with final extension at 72°C
for 10 min. The amplified DNA samples were analyzed
on 2% agarose gel. The DNA bands were visualized
directly under the UV and the photographs of the gels
were obtained with gel documentation system.
Results
Ten medicinal plants were collected from different area
of Pakistan on the basis of undocumented reports for
antiviral screening against HCV. Plants materials were
air dried and extracted in methanol. All information
regarding botanical names, family vernacular names,
local uses and % yield of ten medicinal plants were
shown in Table 1.
Cellular toxicity through MTT Assay
Before starting the antiviral screening against Hepatitis
C virus, toxicological effect of ten medicinal plant
extracts were determined through MTT cell prolifera-
tion assay. The MTT substance is reduced by mitochon-
drial succinic dehydrogenases in living cells to purple
formazan crystals that are not soluble in aqueous water.
The absorption of dissolved formazan in the visible
region correlates with the number of alive cells [20].
Figure 1 exhibited cytotoxic effects of SN and demon-
strated that cell proliferation of liver cells is unaffected
up to a concentration of 100 μM. But when we
exceeded 100 μM toxic effects were observed. Similar
results were observed for additional 9 medicinal extracts
ranging from a concentration of 1 to 100 μM.
Antiviral Assay
Since HCV replication in cell culture is limited to
human hepatocytes and their derivatives, now several
reports have verified that HCV can replicate in Huh-7
cells through detection of viral genes as well as viral
copy number by Real Time PCR in both cells and
supernatant[21]. In the present study, solvent extracts
from different plants were tested to determine the
antiviral activity against HCV. Real time RT-PCR
results showed that Solanum nigrum (SN) out of ten
medicinal plants showed antiviral effect against HCV.
The results demonstrated that methanolic extract of
SN showed 37% inhibition a concentration of HCV
RNA at non toxic concentration (Figure 2). This
extract was further fractionated in different solvents on
the basis of polarity. Significant inhibition against HCV
was shown by Chloroform extract of Solanum nigrum
seeds with more than 50% reduction a concentration
of viral titer (Figure 3).
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Huh-7 cells
To determine the effect of Solanum nigrum extract
against HCV NS3 protease, Huh-7 cells were trans-
fected with NS3 protease plasmid in the presence and
absence of herbal extracts. After 48 hrs incubation,
cells were harvested, RNA was extracted and cDNA
were generated by oligo dT primers. cDNA was
amplified by PCR using primers specific to the HCV
NS3 protease. Amplification of GAPDH mRNA served
as an internal control. Figure 4 demonstrates that
Solanum nigrum chloroform extract inhibits HCV
RNA expression significantly in a dose-dependent
manner along with interferon, while GAPDH mRNA
expression remains unaffected by the addition of the
extract.
Discussion
HCV infection is a serious global health problem neces-
sitating effective treatment. Currently, there is no vac-
cine available for prevention of HCV infection due to
high degree of strain variation. The current treatment of
care, Pegylated interferon a in combination with riba-
virin is costly, has significant side effects and fail to cure
about half of all infections [22,23]. Hence, there is a
need to develop anti-HCV agents from medicinal plants,
which are less toxic, more efficacious and cost-effective.
Previous studies demonstrated that medicinal plants
used for centuries against different diseases including
viral diseases and become a focal point to identify, iso-
late and purify new compounds to treat diseases. Clini-
cal trials have shown that some medicinal herbs might
have therapeutic potential for chronic hepatitis C [24].
Table 1 Medicinal plants selected for anti-HCV activity and %age yield
Plants names Family Local/Vernacular Names Local uses Parts
Used
Extracts %
yield
Trachyspermum
ammi
Apiaceae Ajowan caraway digestive aid and antiseptic Seeds 9.7
Solanum nigrum Solanaceae Black Night Shade, Mako Treat mouth ulcer, antitumour Seeds 11.96
Cichorium intybus Compositae Chakori, kasni Gallstone, gastro-enteritis, jaundice, Seeds 9.25
Phyllanthus amarus Euphorbiaceae Amla Kidney stone, hypertension, jaundice. Leaves 7.33
Schinus molle Anacardiaceae Pink Peppercorns, False pipper
nigrum
Antibacterial, antiseptic, diuretic,
rheumatism
Fruits 24.65
Syzygium
aromaticum
Myrtaceae Clove, lavang Carminative, anthelmintic, pain killer Leaves 22.6
Cordia dichotoma Boraginaceae Clammy cherry, lasoori, gunda, Anti-inflammatory Leaves 14.1
Colocasia esculenta Araceae Kachalu, Arvi Anti-diarrhea, anorexia, antipyretic. Leaves 21.5
Momordica
charantia
Cucurbitaceae Karela, Antiviral dyspepsia, constipation, Leaves 5.9
Cucumis sativus Cucurbitaceae Kheera, trapush, Jaundice, mental stress. Leaves 8.73
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Figure 1 Toxicity of extract of SN through MTT cell
proliferation assay. Huh-7 cells were plated at the density of 2 ×
10
4 in 96 well plates. After 24 h cells were treated with different
concentrations of herbal extracts and control consisted of solvent in
which compound dissolved. After 24 h incubation period add MTT
solution to all wells and incubated for 3-4 h at 37°C.Viable cells
convert MTT to purple formazan crystal. Added DMSO to dissolve
the formazan crystals and read absorbance at 570 nm and 620 nm.
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Figure 2 Anti-HCV activity of methanol extract of Solanum
nigrum. Huh-7 cells were incubated with HCV serum and 100 μg/μl
concentration of Solanum nigrum seeds extract for 24 hours. At the
end of incubation period, total RNA was extracted by Gentra kit,
and the levels of HCV RNA remaining were determined by the
Quantitative RT-PCR assay and are shown as a percentage relative
to the levels of HCV RNA in cells incubated without compound
(control).
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reported to have strong antiviral activity like licorice
root (Glycyrrhizia uralensis). Previous reports showed
that extracted substance, glycyrrhizin sulphate, inhibit
HIV replication, interfere with virus-to-cell binding and
cell-to-cell infection, and induce IFN activity [25]. Sily-
bum marianum (milk thistle) has been shown to have
clinical applications in the treatment of toxic hepatitis,
fatty liver, cirrhosis, ischemic injury, radiation toxicity,
and viral hepatitis via its antioxidative, anti-lipid peroxi-
dative, antifibrotic, anti-inflammatory, immunomodulat-
ing, and liver regenerating effects [26].
In the present study, methanolic extracts of ten medic-
inal plants were tested for antiviral activity and Solanum
nigrum seeds extract was found to exhibit potential
antiviral activity against HCV 3a genotype. Solanum
nigrum (Solanaceae) has been extensively used in tradi-
tional medicine in different parts of world to cure tuber-
culosis, diuresis [27], various nerve disorders [28], ulcer
healing [29] liver disorders [30], antiseizure and inflam-
matory conditions [31]. The methanolic extract of Sola-
num nigrum contains principle components including
flavonoids, saponins, alkaloids, phytosterols [32]. Accord-
ing to our finding, methanolic extract of Solanum nigrum
seeds resulted in 37% reduction in HCV RNA of 3a geno-
type at non toxic concentration (Figure 2).
Further characterization of antiviral active extracts was
performed in different solvents. Our results demon-
s t r a t e dt h a tC h l o r o f o r me x t r a c to fS olanum nigrum
showed convincing decrease in a concentration of viral
titter at non toxic concentration (Figure 3). Previous
studies showed that chloroform extracts mainly contains
saponins, flavonoids and terpenoids [33-35]. So there
could be an excellent therapeutic agent present in this
extract that is waiting to identify and characterize
through various spectroscopic techniques.
HCV NS3 protease is a target for therapeutic interven-
tion of acute and chronic HCV that NS3 mediated pro-
cessing of the polyprotein is essential for HCV RNA
replication and maturation [36]. Furthermore, NS3 may
have other properties involved in interference with host
cell functions like inhibition of protein kinase A-
mediated signal transduction or cell transformation
[37,38]. Previous report demonstrated that ethanol
extract from rhizomes of the Chinese medicinal herb
Rhodiola kirilowii (Regel) exhibited antiviral activity
against HCV NS3 serine protease. Twelve compounds
were isolated by partitioning of the extract between water
and different organic solvents. These compounds were
analysed for in-vitro antiviral activity against HCV NS3-
SP, among which Epicatechin and Epigallocatechin and
their dimers has in-vitro antiviral activity against HCV
NS3-SP [39]. Similarly our data reveals that chloroform
extract directed against HCV NS3 resulted in specific
inhibition of NS3 protease in a dose-dependent manner
while GAPDH remained constant (Figure 4).
On the basis of results presented herein showed that
mehanolic and chloroform extract of Solanum nigrum
seeds play a role in viral clearance during natural HCV
infection. These data also suggest that therapeutic
induction of extracts might represent an alternative
approach for the treatment of chronic HCV infection or
the present study leads to the development of more
potent and orally available HCV therapeutic drug.
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Figure 3 Anti-HCV activity of chloroform and n-hexane fraction
of Solanum nigrum. Huh-7 cells were incubated with HCV serum
and 100 μg/μl concentration of Solanum nigrum seeds extract in
different solvents for 24 hours. At the end of incubation period,
total RNA was extracted by Gentra kit, and the levels of HCV RNA
remaining were determined by the Quantitative RT-PCR assay and
are shown as a percentage relative to the levels of HCV RNA in cells
incubated without compound (control).
Figure 4 Antiviral effect of chloroform extract of Solanum
nigrum against HCV NS3 protease. Huh-7 cells were transfected
with 0.5 μg of constructed HCV NS3 protease vector in the
presence and absence of SN and interferon for 24 48 hrs. Cells were
harvested and relative RNA determinations were carried out using
semi-quantitative RT-PCR. The results demonstrated that SN and
interferon inhibit HCV NS3 expression while the expression of
GAPDH remained constant.
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